Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab

Shogo Yamaguchi; Ryota Morimoto; Takahiro Okumura; Yuta Yamashita; Tomoaki Haga; Tasuku Kuwayama; Tsuyoshi Yokoi; Hiroaki Hiraiwa; Toru Kondo; Yuki Sugiura; Naoki Watanabe; Naoaki Kano; Kei Kohno; Kenji Fukaya; Akinori Sawamura; Kenji Yokota; Hideki Ishii; Masato Nakaguro; Masashi Akiyama; Toyoaki Murohara

doi:10.1016/j.cjca.2018.03.007

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab

Shogo Yamaguchi, Ryota Morimoto, Takahiro Okumura, Yuta Yamashita, Tomoaki Haga, Tasuku Kuwayama, Tsuyoshi Yokoi, Hiroaki Hiraiwa, Toru Kondo, Yuki Sugiura, Naoki Watanabe, Naoaki Kano, Kei Kohno, Kenji Fukaya, Akinori Sawamura, Kenji Yokota, Hideki Ishii, Masato Nakaguro, Masashi Akiyama, Toyoaki Murohara

Internal Medicine

Research output: Contribution to journal › Article › peer-review

58 Citations (Scopus)

Abstract

A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20− and programmed death-1− markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.

Original language	English
Pages (from-to)	812.e1-812.e3
Journal	Canadian Journal of Cardiology
Volume	34
Issue number	6
DOIs	https://doi.org/10.1016/j.cjca.2018.03.007
Publication status	Published - 06-2018

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cjca.2018.03.007

Cite this

Yamaguchi, S., Morimoto, R., Okumura, T., Yamashita, Y., Haga, T., Kuwayama, T., Yokoi, T., Hiraiwa, H., Kondo, T., Sugiura, Y., Watanabe, N., Kano, N., Kohno, K., Fukaya, K., Sawamura, A., Yokota, K., Ishii, H., Nakaguro, M., Akiyama, M., & Murohara, T. (2018). Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab. Canadian Journal of Cardiology, 34(6), 812.e1-812.e3. https://doi.org/10.1016/j.cjca.2018.03.007

@article{ca759e7edfd64b0397c89608a9e3f523,

title = "Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab",

abstract = "A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20− and programmed death-1− markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.",

author = "Shogo Yamaguchi and Ryota Morimoto and Takahiro Okumura and Yuta Yamashita and Tomoaki Haga and Tasuku Kuwayama and Tsuyoshi Yokoi and Hiroaki Hiraiwa and Toru Kondo and Yuki Sugiura and Naoki Watanabe and Naoaki Kano and Kei Kohno and Kenji Fukaya and Akinori Sawamura and Kenji Yokota and Hideki Ishii and Masato Nakaguro and Masashi Akiyama and Toyoaki Murohara",

note = "Publisher Copyright: {\textcopyright} 2018 Canadian Cardiovascular Society",

year = "2018",

month = jun,

doi = "10.1016/j.cjca.2018.03.007",

language = "English",

volume = "34",

pages = "812.e1--812.e3",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Pulsus Group Inc.",

number = "6",

}

Yamaguchi, S, Morimoto, R, Okumura, T, Yamashita, Y, Haga, T, Kuwayama, T, Yokoi, T, Hiraiwa, H, Kondo, T, Sugiura, Y, Watanabe, N, Kano, N, Kohno, K, Fukaya, K, Sawamura, A, Yokota, K, Ishii, H, Nakaguro, M, Akiyama, M & Murohara, T 2018, 'Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab', Canadian Journal of Cardiology, vol. 34, no. 6, pp. 812.e1-812.e3. https://doi.org/10.1016/j.cjca.2018.03.007

TY - JOUR

T1 - Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab

AU - Yamaguchi, Shogo

AU - Morimoto, Ryota

AU - Okumura, Takahiro

AU - Yamashita, Yuta

AU - Haga, Tomoaki

AU - Kuwayama, Tasuku

AU - Yokoi, Tsuyoshi

AU - Hiraiwa, Hiroaki

AU - Kondo, Toru

AU - Sugiura, Yuki

AU - Watanabe, Naoki

AU - Kano, Naoaki

AU - Kohno, Kei

AU - Fukaya, Kenji

AU - Sawamura, Akinori

AU - Yokota, Kenji

AU - Ishii, Hideki

AU - Nakaguro, Masato

AU - Akiyama, Masashi

AU - Murohara, Toyoaki

PY - 2018/6

Y1 - 2018/6

N2 - A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20− and programmed death-1− markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.

AB - A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20− and programmed death-1− markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.

UR - http://www.scopus.com/inward/record.url?scp=85047440701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047440701&partnerID=8YFLogxK

U2 - 10.1016/j.cjca.2018.03.007

DO - 10.1016/j.cjca.2018.03.007

M3 - Article

C2 - 29801747

AN - SCOPUS:85047440701

SN - 0828-282X

VL - 34

SP - 812.e1-812.e3

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

IS - 6

ER -

Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this